HemaSphere (Jun 2022)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

  • M. J. van Dijk,
  • M. A. Rab,
  • B. A. van Oirschot,
  • J. Bos,
  • C. Derichs,
  • A. W. Rijneveld,
  • M. H. Cnossen,
  • E. Nur,
  • B. J. Biemond,
  • M. Bartels,
  • J. J. Jans,
  • W. W. van Solinge,
  • R. E. Schutgens,
  • R. van Wijk,
  • E. J. van Beers

DOI
https://doi.org/10.1097/01.HS9.0000848860.58516.71
Journal volume & issue
Vol. 6
pp. 1382 – 1383

Abstract

Read online

No abstracts available.